



Summary of Consolidated Results for 1H FY07 and Projection for FY07

Hiroshi Takahara
Corporate Officer, General Manager,
Finance & Accounting Dept.



Takeda Pharmaceutical Company Limited

Outline of Consolidated Results

【Unit: billions of yen】

	1H FY06	1H FY07	Year-on-year change		
				%	
Net sales	642.4	708.5	66.0	10.3	9th consecutive-year growth
Operating income	236.2	264.9	28.7	12.1	2nd consecutive-year growth
Ordinary income	299.0	333.7	34.7	11.6	9th consecutive-year growth
Net income	159.1	218.0	58.9	37.0	Increased after 1 year of decline
R&D expenses	96.2	107.3	11.1	11.6	
EPS	181.27 yen	255.54 yen	74.27 yen	41.0	

2

Takeda Pharmaceutical Company Limited

Actos Growth


<Comparison of 1H FY07 with 1H FY06>

Year-on-year change
%

	Worldwide	+46.0	+28.6%
Japan	+4.1	+25.6%	
Asia	+0.4	+33.8%	
Europe	+4.2	+39.7%	
Americas	+37.3	+28.0%	

(*On a consolidated basis; excluding sales by affiliates)

【Unit: billions of yen】



Takeda Pharmaceutical Company Limited

Currency Translation Impact


(Comparison with 1H FY06)

【Unit: billions of yen】

			Net sales	Operating income	Ordinary income	Net income
Increase/Decrease from the same period of last year			+66.0	+28.7	+34.7	+58.9
USD	+4 yen (115 119)	Currency Translation Impact	+7.2	+3.2	+5.0	+3.4
EUR	+16 yen (146 162)		+6.3	+1.1	+1.5	+0.4
Other currencies	-		+1.4	-0.0	+0.1	+0.1
Total			+14.9	+4.3	+6.7	+3.9
Results excluding currency translation impact			+51.2	+24.4	+28.0	+55.0

Takeda Pharmaceutical Company Limited

Components of Sales Increase/Decrease



Sales of ethical pharmaceutical products in Japan


【Unit: billions of yen】

	1H FY06	1H FY07	Year-on-year change %	
<i>Blopress</i>	63.2	68.6	5.4	8.5
<i>Leuplin</i>	32.2	33.3	1.1	3.5
<i>Takepron</i>	28.3	31.5	3.2	11.2
<i>Basen</i>	28.4	27.1	- 1.2	- 4.4
<i>Actos</i>	16.0	20.1	4.1	25.6
<i>Enbrel</i>	5.1	8.5	3.4	66.7

6


Takeda Pharmaceutical Company Limited

Components of Sales Increase/Decrease at TPNA



Sales of In-house Ethical Products by Region

(Total global sales including affiliates)



International strategic products Sales

(Worldwide sales, including sales by affiliates)

【Unit: billions of yen】


	1H FY06	1H FY07	Year-on-year change		Regional Increase/Decrease			
				%	Japan	Americas	Europe	Asia
<i>Pioglitazone</i>	161.4	207.7	46.3	28.7	4.1	37.3	4.2	0.7
<i>Lansoprazole</i>	196.8	190.7	- 6.2	- 3.1	3.2	- 9.5	- 0.1	0.3
<i>Candesartan</i>	100.9	113.3	12.4	12.3	5.4	Overseas total		7.0
<i>Leuprorelin</i>	91.4	92.8	1.5	1.6	1.1	- 1.1	1.0	0.5
Four international strategic products	550.5	604.5	54.1	9.8	13.8	Overseas total		40.3

9

Takeda Pharmaceutical Company Limited

Consolidated Operating Income Key Factors

【Unit: billions of yen】




10

Takeda Pharmaceutical Company Limited

Consolidated Net Income Key Factors

【Unit: billions of yen】



11

Takeda Pharmaceutical Company Limited

FY 2007 Outlook Financial Summary

【Unit: billions of yen】

	FY06 Actual	FY07 Est. as of '07/5	FY07 Est. as of '07/11	Year-on-year change	%
Net sales	1,305.2	1,390.0	1,400.0	94.8	7.3
Operating income	458.5	470.0	485.0	26.5	5.8
Ordinary income	585.0	585.0	605.0	20.0	3.4
Net income	335.8	380.0	395.0	59.2	17.6
R&D expenses	193.3	230.0	230.0	36.7	19.0
EPS	386.00 yen	442.18 yen	465.58 yen	79.58 yen	20.6


12

Takeda Pharmaceutical Company Limited

Returns to Shareholders

(billions of yen)

	FY06	1H FY07	Total
Share buy-back	213.5	128.6	342.0



13